PDF(Pubmed)
Abstract：
Type 1 Diabetes Mellitus (T1DM) can generate severe complications, such as Diabetic Kidney Disease (DKD) or Diabetic Nephropathy (DN), with it emerging as the leading cause of terminal (end-stage) renal disease all over the world. For T1DM, the clinical evaluation of DKD uses markers like the Glomerular Filtration Rate (GFR) and the Urinary Albumin Excretion (UAE). However, early diagnosis of DKD is still a challenge. For this reason, investigating molecular markers, such as microRNAs (miRNAs), offers a promising perspective to an early diagnosis, highlighting the stability and the ability to reflect incipient molecular manifestations. Thus, here we investigated four miRNAs (hsa-let-7i-5p, hsa-miR-143-3p, hsa-miR-501-3p, and hsa-miR-100-5p) regarding nephropathy in patients with T1DM, considering the albuminuria (micro and macro) as a standard to evaluate the groups. As a result, we found a reduced expression of miR-100-5p in patients with MIC, indicating a protective role in nephropathy. Beyond that, expression levels between the groups (Non vs. UAE) were not significant when comparing the miRNAs miR-501-3p and miR-143-3p. Finally, miR-143-3p and miR-100-5p were linked to some target genes such as AKT1, MMP13, and IGF1R, that are connected to signal pathways and cellular metabolism.
摘要：
1型糖尿病（T1DM）可产生严重的并发症，如糖尿病肾病（DKD）或糖尿病肾病（DN），随着它成为全球晚期（终末期）肾病的主要原因。对于T1DM，DKD的临床评估使用肾小球滤过率(GFR)和尿白蛋白排泄(UAE)等标志物.然而,DKD的早期诊断仍然是一个挑战。出于这个原因,研究分子标记，如microRNAs（miRNAs），为早期诊断提供了一个有希望的观点，强调稳定性和反映早期分子表现的能力。因此，在这里，我们研究了四个miRNA（hsa-let-7i-5p，hsa-miR-143-3p,hsa-miR-501-3p,和hsa-miR-100-5p）关于T1DM患者的肾病，考虑白蛋白尿（微观和宏观）作为评估组的标准。因此,我们发现miR-100-5p在MIC患者中的表达降低，表明在肾病中具有保护作用。除此之外，组间表达水平(非vs.UAE）在比较miRNAmiR-501-3p和miR-143-3p时不显著。最后,miR-143-3p和miR-100-5p与一些靶基因如AKT1、MMP13和IGF1R相关。与信号通路和细胞代谢有关。
